Ellicott City, MD, United States of America

Takashi Tsukamoto

This inventor holds 22 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Cancer Therapeutics. Top assignees: Guilford Pharmaceuticals, Inc., Johns Hopkins University, Eisai Inc.. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Tsukamoto. Retrieved from https://idiyas.com/inventor/takashi-tsukamoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 2)

% Patents Active = 54.5

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 109(Granted Patents)

Location History:

Baltimore, MD (US) (2000)
Ellicott City, MD (US) (2002 - 2021)

Company Filing History:

12 out of 98

Guilford Pharmaceuticals, Inc.

patents

4 out of 3,806

Johns Hopkins University

Otsuka Pharmaceutical Company, Limited

patents

5. 1 out of 4

Eisai Corporation of North America

patents

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

nSMase2 Inhibitors

Glutaminase Inhibitors

Cancer Therapy

Thiolactones

NAALADase Inhibitors

Compounds

Pharmacological Levels

High-Throughput Methods

Thiol-Based Inhibitors

Benzenedicarboxylic Acids

Phosphinic Acids

Acyl Hydroxamines

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195450 - Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors (2025-01-14),

2. 11191732 - Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy (2021-12-07),

3. 9567363 - Certain compounds, compositions and methods (2017-02-14),

4. 9505753 - Inhibitors of D-amino acid oxidase (2016-11-29),

5. 8951987 - Certain compounds, compositions and methods (2015-02-10),

6. 8778688 - High-throughput methods for determining pharmacological levels of plasma D-serine (2014-07-15),

7. 8618075 - Certain compounds, compositions and methods (2013-12-31),

8. 8268800 - Certain compounds, compositions and methods (2012-09-18),

9. 7968593 - Thiolactones (2011-06-28),

10. 7553866 - Thiolactones (2009-06-30),

11. 7148250 - Indoles as NAALADase inhibitors (2006-12-12),

12. 7138543 - Thiolalkyl benzoic acid derivatives (2006-11-21),

13. 7125907 - Thiolactones (2006-10-24),

14. 6992215 - Thiol-based NAALADase inhibitors (2006-01-31),

15. 6884907 - Hydroxamic acids and acyl hydroxamines as naaladase inhibitors (2005-04-26),

Title: Innovations in Cancer Therapy and Neurodegenerative Diseases: The Contributions of Takashi Tsukamoto

Introduction

Takashi Tsukamoto is an accomplished inventor based in Ellicott City, MD, known for his groundbreaking work in the field of medical research. With a notable portfolio of 22 patents, his innovative contributions are making significant strides in the treatment of neurodegenerative diseases and cancer.

Latest Patents

Takashi Tsukamoto's recent patents focus on two key areas. The first is the development of small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) aimed at treating neurodegenerative diseases associated with high levels of ceramide, such as Alzheimer’s disease, HIV-associated neurocognitive disorder, multiple sclerosis, and amyotrophic lateral sclerosis. The second patent addresses glutaminase inhibitors formulated for nanoparticle-enhanced delivery. This innovation improves the treatment of pancreatic cancer and other malignancies that rely on glutamine by enhancing drug solubility, delivery, and overall efficacy through the use of colloidal nanoparticles.

Career Highlights

Throughout his career, Takashi has played a pivotal role in advancing medical research. He has contributed to reputable organizations, including Guilford Pharmaceuticals, Inc. and The Johns Hopkins University, where his skills and insights have led to significant advancements in therapeutic options for complex diseases.

Collaborations

Takashi Tsukamoto has worked alongside esteemed colleagues such as Barbara S. Slusher and Doris Stoermer. Together, they have pushed the boundaries of innovation and contributed to collaborative research efforts, further enhancing the scientific community’s understanding of neurodegenerative conditions and cancer treatments.

Conclusion

In conclusion, Takashi Tsukamoto stands out as a prominent inventor who is reshaping the landscape of medical treatment with his innovative patents. His work not only addresses pressing health issues but also exemplifies the impact of collaboration within research institutions. As the medical field continues to evolve, the contributions of inventors like Tsukamoto will play a critical role in developing effective therapies for complex diseases.

Profile summary based on public USPTO records.